Dr Deirdre Lane PhD, FRCPE, FHEA, FESC, BSc

Dr Deirdre Lane

Institute of Cardiovascular Sciences
Senior Lecturer in Cardiovascular Health

Contact details

Institute of Cardiovascular Sciences, University of Birmingham
City Hospital, Sandwell and West Birmingham Hospitals NHS Trust
Dudley Road
B18 7QH

Dr Deirdre Lane is a Senior Lecturer in Cardiovascular Health and Adjunct Professor of Cardiovascular Health at Aalborg University, Denmark.  She is involved in teaching undergraduate and graduate entry medical students, postgraduate courses, and in the supervision of undergraduate, postgraduate and doctoral students.

Her research is primarily concerned with stroke and bleeding risk in atrial fibrillation and in patient’s perceptions and understanding of the disease and its’ treatment, subjects on which she has published extensively.  In addition, she often gives talks to variety of audiences at both the national and international level on these topics.  She is also a member of the most recent American College of Chest Physician guidelines on antithrombotic therapy in atrial fibrillation patients and the European Heart Rhythm Association Scientific Documents Committee.  She has also been involved in the development of the European Heart Rhythm Association patient website for atrial fibrillation and the NHS Shared Decision Making patient decision aid for stroke prevention for atrial fibrillation or atrial flutter.


  • Fellow of the European Society of Cardiology 2015
  • Postgraduate Certificate in Academic Practice 2013
  • Fellow of the Royal College of Physicians Edinburgh 2012
  • Fellow of the Higher Education Academy 2012
  • PhD 2000
  • BSc (Hons) Psychology 1995


Dr Lane received a BSc (Hons) in Psychology from the University of Liverpool in 1995.  She went on to study for a PhD at the University of Birmingham in 1996.  Following the award of her PhD, she worked as an Academic Fellow and Honorary Non-Clinical Lecturer in the University Department of Medicine, Sandwell and West Birmingham Hospitals NHS Trust, until joining the University in February 2010.

Her main research interest is atrial fibrillation (AF), particularly how AF affects quality of life and psychological well-being, and patient perceptions’ of the condition.  She is the principal investigator for a NIHR-funded randomised controlled trial (RCT) comparing cognitive-behavioural therapy with usual care in AF patients with anxiety and/or depression (CBT-AF).  She was also the principal investigator for a RCT (TREAT) in AF patients newly referred for oral anticoagulation (OAC), to examine the impact of education on patients’ knowledge and perceptions of AF and its treatment, and anticoagulation control compared to usual care.  She is also involved in qualitative research examining the patients’ experience of AF and OAC therapy, and physicians’ attitudes to AF and OAC prescription.  In collaboration with colleagues, she has been integral in refining the risk stratification of AF patients requiring OAC therapy based on their bleeding and stroke risk, and has helped to derive and validate stroke (CHA2DS2-VASc) and bleeding (HAS-BLED) risk schemas which are widely used both nationally and internationally in clinical practice.  Her background is in health psychology and cardiovascular epidemiology and other research interests include hypertension, heart failure, cardiac rehabilitation, and ethnic differences in cardiovascular disease.  Dr Lane is also involved in clinical trials and registry studies related to atrial fibrillation. She is currently the UK co-ordinator for both the European AF-GEN study and the UK extension (AF-GEN-UK) study, which are registries of atrial fibrillation management.

Her research has received a number of awards over the last 5 years.  In September 2012 she was one of the recipients of the Atrial Fibrillation Association Team of the Year award for her work in the refinement of stroke risk stratification in atrial fibrillation patients.  She has also awarded the BMJ Cardiovascular Team of the Year award (in conjunction with Professor Lip) for her work in the development and validation of the HAS-BLED bleeding risk score and its impact on clinical practice and patient safety. Her research group was shortlisted as Finalists for the BMJ Innovation Award 2014 and the BMA Quality in Anticoagulation Awards 2014 in relation to the TREAT intervention. More recently, together with colleagues she was awarded a CRN West Midlands Clinical Research Impact Award (2016) and two NHS Trust Awards for Excellence in Research (2016) and the Beacon Service Award for Research (2016). 


  • Postgraduate

CPD Management of Atrial Fibrillation: Module Lead

UndergraduateMBChB Intercalation BMedSc (Population and Health Sciences)

Deputy Course Director

Programme Lead for Public Health

Research Project Supervisor

  • MBChB

Joint Component Lead for Decision Making (DEM), Foundations 4 (Year 2, Semester 2)

Small Group Teaching for Foundations 1-4 (Years 1 & 2)

Student Selected Component (SSC) Clinical Audit (Year 4)

Elective placement supervisor (Year 4)

  • Graduate Entry Course (GEC)
  • Personal Mentor

Postgraduate supervision

Dr Lane supervises doctoral students in areas related to her research interests.  She is currently supervising a PhD student examining factors influencing anticoagulation control and co-supervising a MD student examining bleeding risk in atrial fibrillation patients.

She currently has openings for self-funded PhD students in areas-related to her research.  If you are interested in studying in any of these subject areas or related-subject areas please contact Dr Lane on d.a.lane@bham.ac.uk.

For general doctoral research enquiries, please e-mail: dr@contacts.bham.ac.uk or call +44 (0)121 414 5005.

For a full list of available Doctoral Research opportunities, please visit our Doctoral Research programme listings www.bham.ac.uk/postgraduate/courses/findaphd.aspx



Atrial fibrillation; Stroke prevention; Patient-centred research; Stroke risk stratification; Bleeding risk with oral anticoagulation; Health Psychology; Evidence synthesis

The main emphasis of her work over the last 12 years has been atrial fibrillation, with two major themes: bleeding and stroke risk stratification and patient-centred research.  Other research interests include cardiovascular epidemiology particularly hypertension, ethnic differences in cardiovascular disease, cardiac rehabilitation, and psychological responses to myocardial infarction, diabetes mellitus, and heart failure.


Bleeding risk stratification

Reducing the risk of bleeding-related complications for atrial fibrillation (AF) patients requiring oral anticoagulation to prevent stroke is one Dr Lane’s main interests.  In collaboration with national and international colleagues she has helped to identify bleeding risk factors among AF patients and has derived a novel bleeding risk score.  The HAS-BLED schema has been incorporated into major national and international guidelines for the management of atrial fibrillation.  In addition, her ongoing work is validating the HAS-BLED schema in other AF cohorts and seeking to identify novel blood biomarkers which may further refine bleeding risk in the AF population.

Stroke risk stratification

She has also been involved in identifying ‘new’ risk factors for stroke among AF patients and in conjunction with national and international colleagues she has helped to refine stroke risk assessment, by devising the CHA2DS2-VASc schema.  Her research has involved comparison of CHA2DS2-VASc with other contemporary stroke risk schemas in different cohorts of AF patients.  This has led to the incorporation of the CHA2DS2-VASc schema into national and international guidelines for the management of AF patients.  The CHA2DS2-VASc schema allows the identification of truly low risk AF patients who may not require antithrombotic therapy, while oral anticoagulation is considered all other patients.  This has led to a significant shift in clinical practice, in conjunction with the availability of novel oral anticoagulants with their improved safety profile.

Patient-centred research

One of her major interests is the patient and how they adapt to diseases/illnesses.  Most recently, her research has focussed on AF patients.  Patient perceptions and understanding of disease and its treatment, and identification of patient barriers to treatment are fundamental to their acceptance and adherence to therapy, which is particularly important in chronic treatments which also require lifestyle modification, such as AF patients requiring lifelong oral anticoagulation therapy.  Recent research has employed both quantitative and qualitative methodology to explore the patient experience of AF and treatment.  She is the principal investigator for a randomised controlled trial comparing cognitive-behavioural therapy to usual care in atrial fibrillation patients who are anxious and/or depressed.  Qualitative research has examined the patients’ experience of AF and OAC therapy, and physicians’ attitudes to AF and OAC prescription. 

Evidence synthesis

Dr Lane was the principal investigator for an NIHR Health Technology Assessment funded systematic review of the effects of combination antithrombotic therapy on vascular events in high-risk (post-acute coronary syndromes and/or stent implantation) AF patients.  She has also led a number of Cochrane Reviews, most recently examining the effect of education and behavioural interventions on anticoagulation therapy in atrial fibrillation patients. 

Other activities

  • American College of Chest Physicians Guideline Committee- Antithrombotic therapy in atrial fibrillation patients, 10th Edition [2016-2018]
  • Heart International Advisory Board Member [1 January 2016 – 3 year term]
  • European Heart Rhythm Association Scientific Documents Writing Committee [July 2015- Second 2 year term]
  • AEGEAN Steering Committee Member - European Phase IV programme to assess adherence to apixaban and the effects of a patient educational program[October 2012-present]
  • European Heart Rhythm Association Task Force Chair - Cardiac tachyarrhythmias and patient values and preferences for their management [2013-2015]
  • European Heart Rhythm Association Website and Communication Committee [September 2013- September 2015]
  • European Heart Rhythm Association Scientific Documents Writing Committee [July 2013- July 2015]
  • International Advisory Committee member- Serbian Atrial Fibrillation Association [May 2013- ongoing]
  • European Heart Rhythm Association Task Force Member –Development of a patient-centred educational website for atrial fibrillation – www.afibmatters.org [2013]
  • Department of Health Medical Advisory Group for Atrial Fibrillation- Development of a patient decision aid  for stroke prevention in atrial fibrillation [2012]
  • American College of Chest Physicians Guideline Committee- Antithrombotic therapy in atrial fibrillation patients, 9th Edition [2010-2011]
  • Panellist on the European Heart Rhythm Association Bleeding Task Force [2010-2011]


Selected publications (2015-2017)

>200 peer-reviewed publications; H-index: 45 (March 2017)

Lane, D.A., Skjøth, F., Lip, G.Y.H., Larsen, T.B., Kotecha, D. (2017). Temporal trends in incidence, prevalence and mortality of atrial fibrillation in primary care. JAHA; in press. doi:10.1161/JAHA.116.005155

Clarkesmith, D.E., Pattison, H.M., Lane, D.A. (2017). Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation. Cochrane Database Syst Rev.; in press.

Clarkesmith, D.E., Lip, G.Y.H., Lane, D.A. (2017)  Patients' experiences of living with atrial fibrillation and taking dabigatran for stroke prevention: a qualitative study. Thromb Res; in press.doi:10.1016/j.thromres.2017.03.002

Kotecha, D., Ahmed, A., Calvert, M., Lencioni, M., Terwee, C.B., Lane, D.A. (2016) Patient-reported outcomes for quality of life assessment in atrial fibrillation: A systematic review of measurement properties. PLoS ONE; 11(11): e0165790.  doi:10.1371/journal.pone.0165790.

Borg Xuereb, C., Shaw, R.L, Lane, D.A. (2016) Patients’ and physicians’ experiences of atrial fibrillation consultations and anticoagulation decision-making: A multi-perspective IPA design. Psychol Health; 31: 436-455.

Proietti, M., Senoo, K., Lane, D.A., Lip, G.Y.H. (2016). Major bleeding in patients with non-valvular atrial fibrillation: Impact of time in therapeutic range on contemporary bleeding risk scores. Sci Rep; 6: 24376. doi:10.1038/srep24376.

Lip, G.Y.H., Fauchier, L., Freedman, S.B., van Gelder, I., Natale, A., Gianni, C., Nattel, S., Potpara, T., Rienstra, M., Tse, H-F., Lane, D.A. (2016) Atrial fibrillation. Nat Rev Dis Primers; 2:16016. doi: 10.1038/nrdp.2016.1

Lane DA, Aguinaga L, Blomström-Lundqvist C, et al. (2015). Cardiac tachyarrhythmias and patient values and preferences for their management: the European Heart Rhythm Association (EHRA) consensus document endorsed by HRS, APHRS, and SOLEACE. Europace. 17(12): 1747-1769. doi: 10.1093/europace/euv233

Lip, G.Y.H., Lane, D.A. (2015). Stroke prevention in atrial fibrillation: A systematic review. JAMA; 313; 1950-1962.

Gorst-Rasmussen, A., Skjøth, F., Larsen, T.B., Rasmussen, L.H., Lip, G.Y.H., Lane, D.A. (2015) Dabigatran adherence in atrial fibrillation patients during the first year after diagnosis: a nationwide cohort study. J Thromb Haemost; 13: 495-504. doi:10.1111/jth.12845.

Melgaard, L., Gorst-Rasmussen, A., Lane, D.A., Rasmussen, L.H., Larsen, T.B., Lip, G.Y. (2015). Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA; 314:1030-8. doi: 10.1001/jama.2015.10725.

Lane, D.A., Barker, R.V., Lip, G.Y.H. (2015).  Best practice for atrial fibrillation patient education. Curr Pharm Des; 21: 533-543.

Shantsila, E., Wolff, A., Lip, G.Y.H., Lane, D.A. (2015) Optimising stroke prevention in patients with atrial fibrillation: Application of the GRASP-AF audit tool in a general practice cohort. Br J Gen Pract 2015; 65; e16-23. doi: 10.3399/bjgp15X683113.